Last month we read about a move by the FDA to increase its rare disease efforts. The impact on pediatric sarcoma research remains to be seen, but we are hopeful!
FDA to Revamp Rare Disease Efforts
The US government agency vows to improve the way it facilitates the development and approval of drugs for orphan diseases.
By Bob Grant | September 12, 2011
No comments:
Post a Comment